The relationship between monocyte subsets and IL-37 changes after allogeneic hematopoietic stem cell transplantation and acute graft-versus-host disease

doi:10.11958/20253702

Abstract

Abstract:

Objective To investigate changes of peripheral blood monocyte subsets and interleukin-37 (IL-37) levels following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their association with the occurrence and severity of acute graft-versus-host disease (aGVHD). Methods A total of 40 patients underwent allo-HSCT and 25 healthy individuals were enrolled. Patients were followed up to 100 days post-transplantation. Patients were categorized into the aGVHD group and the non-aGVHD group based on whether aGVHD occurred. Peripheral blood samples were collected at the first follow-up visit post-transplantation and at the onset of aGVHD. Flow cytometry was used to detect the proportions of classical (cMo), intermediate (iMo) and non-classical (ncMo) peripheral blood monocytes. Plasma IL-37 levels were measured by enzyme-linked immunosorbent assay (ELISA). The differences of the above indicators were compared between the three groups. The sensitivity analysis, trend tests and correlation analyses were performed. Results There were significant differences in the proportions of cMo and iMo and IL-37 levels among the three groups (all P<0.01), whereas there was no significant difference in the proportion of ncMo (P>0.05). Post-hoc testing showed that lower cMo and IL-37, and higher iMo were found in the aGVHD group compared with those of the control group. IL-37 was lower in non-aGVHD vs controls (all P_adj<0.05). Findings were consistent in sensitivity analysis (all P<0.05). Trend analysis indicated that decreasing cMo and IL-37 and increasing iMo were in the three groups (all P<0.05). In patients with hematological malignancies underwent allo-HSCT, IL-37 levels were positively correlated with cMo and negatively correlated with iMo (all P<0.05). In aGVHD group, IL-37 correlated negatively and iMo positively with grade (all P<0.05). Conclusion Following allo-HSCT, peripheral blood exhibits immune alterations characterized by increased iMo proportion and decreased IL-37 levels, which are associated with the occurrence and severity of aGVHD.

Key words: acute graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, monocyte, interleukin-37

CLC Number:

R559

Figures/Tables 4

References 21

[1]	Piekarska A, Abouqateb M, Boreland W, et al. Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors-an EBMT registry study by the Transplant Complications Working Party[J]. Bone Marrow Transplant, 2025, 60(12):1574-1583. doi:10.1038/s41409-025-02692-1.
[2]	Daneshmandi S, Ko E, Yan Q, et al. Targeting the pentose phosphate pathway mitigates graft-versus-host disease by rewiring alloreactive T cell metabolism[J]. JCI Insight, 2025, 10(23):e192774. doi:10.1172/jci.insight.192774.
[3]	Reinhardt-Heller K, Hirschberg I, Lang P, et al. Increase of intermediate monocytes in graft-versus-host disease:correlation with MDR1+Th17.1 levels and the effect of prednisolone and 1α,25-dihydroxyvitamin D3[J]. Biol Blood Marrow Transplant, 2017, 23(12):2057-2064. doi:10.1016/j.bbmt.2017.08.008.
[4]	Sun H, Wu L, Zhao X, et al. Monocytes as an early risk factor for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2024, 15:1433091. doi:10.3389/fimmu.2024.1433091.
[5]	Yang Y, Zhang X, Zhang D, et al. Abnormal distribution and function of monocyte subsets in patients with primary immune thrombocytopenia[J]. Clin Appl Thromb Hemost, 2017, 23(7):786-792. doi:10.1177/1076029616652726.
[6]	Ishii A, Nakayamada S, Ohkubo N, et al. Reduction of non-classical monocytes that suppress interferon-α in patients with systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2025, 43(9):1568-1576. doi:10.55563/clinexprheumatol/ziktdx.
[7]	Liao X, Liu J, Guo X, et al. Origin and function of monocytes in inflammatory bowel disease[J]. J Inflamm Res, 2024, 17:2897-2914. doi:10.2147/JIR.S450801.
[8]	Su Z, Tao X. Current understanding of IL-37 in human health and disease[J]. Front Immunol, 2021, 12:696605. doi:10.3389/fimmu.2021.696605.
[9]	中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ)—急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志, 2020, 41(7):529-536.
	Stem Cell Application Group of The Hematology Branch of The Chinese Medical Association. Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease(Ⅲ)—acute graft-versus-host disease(2020)[J]. Chinese Journal of Haematology, 2020, 41(7):529-536. doi:10.3760/cma.j.issn.0253-2727.2020.07.001.
[10]	Rowlings P A, Przepiorka D, Klein J P, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade[J]. Br J Haematol, 1997, 97(4):855-864. doi:10.1046/j.1365-2141.1997.1112925.x.
[11]	王秀娟, 布阿斯亚木·喀迪尔江, 王洪波, 等. Ⅰ型固有淋巴细胞及相关细胞因子在原发免疫性血小板减少症中的变化及临床意义[J]. 天津医药, 2025, 53(8):791-795.
	Wang X J, Kadierjiang B, Wang H B, et al. Changes and clinical significance of type I innate lymphoid cells and associated cytokines in primary immune thrombocytopenia[J]. Tianjin Med J, 2025, 53(8):791-795. doi:10.11958/20251351.
[12]	Kapellos T S, Bonaguro L, Gemünd I, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases[J]. Front Immunol, 2019, 10:2035. doi:10.3389/fimmu.2019.02035.
[13]	Wong K L, Yeap W H, Tai J J, et al. The three human monocyte subsets:implications for health and disease[J]. Immunol Res, 2012, 53(1/2/3):41-57. doi:10.1007/s12026-012-8297-3.
[14]	Salnikova D I, Nikiforov N G, Postnov A Y, et al. Target role of monocytes as key cells of innate immunity in rheumatoid arthritis[J]. Diseases, 2024, 12(5):81. doi:10.3390/diseases12050081.
[15]	Li A, Abraham C, Wang Y, et al. New insights into the basic biology of acute graft-versus-host-disease[J]. Haematologica, 2020, 105(11):2540-2549. doi:10.3324/haematol.2019.240291.
[16]	Rudloff I, Cho S X, Lao J C, et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells[J]. J Leukoc Biol, 2017, 101(4):901-911. doi:10.1189/jlb.3MA0616-287R.
[17]	Teufel L U, Matzaraki V, Folkman L, et al. Insights into the multifaceted role of interleukin-37 on human immune cell regulation[J]. Clin Immunol, 2024, 268:110368. doi:10.1016/j.clim.2024.110368.
[18]	Cavalli G, Tengesdal I W, Gresnigt M, et al. The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity[J]. Cell Rep, 2021, 35(1):108955. doi:10.1016/j.celrep.2021.108955.
[19]	Zeiser R, Chen Y B, Youssef N N, et al. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2[J]. Br J Haematol, 2023, 201(4):620-627. doi:10.1111/bjh.18778.
[20]	Reid K T, Colpitts S J, Mathews J A, et al. Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses[J]. Cell Rep, 2025, 44(1):115102. doi:10.1016/j.celrep.2024.115102.
[21]	Lin M T, Storer B, Martin P J, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation[J]. N Engl J Med, 2003, 349(23):2201-2210. doi:10.1056/NEJMoa022060.

组别		n		年龄/岁		性别				HLA相合程度
组别		n		年龄/岁		男	女			单倍体	全相合
健康对照组		25		32（29，49）		16（64.0）	9（36.0）			-
non-aGVHD组		18		46（22，53）		12（66.7）	6（33.3）			12（66.7）	6（33.3）
aGVHD组		22		42（28，51）		15（68.2）	7（31.8）			14（63.6）	8（36.4）
H、χ²或P				0.127		0.094				1.000^▲
组别	最终检测样本采血时间/d						预处理化疗强度
组别	最终检测样本采血时间/d						清髓性		减低剂量
健康对照组	-						-		-
non-aGVHD组	35.7±5.8						13（72.2）		5（27.8）
aGVHD组	44.1±18.3						17（77.3）		5（22.7）
t或P	1.862						0.731^▲
组别			原发病类型
组别			AML		ALL			MDS
健康对照组			-		-			-
non-aGVHD组			6（33.3）		4（22.2）			8（44.4）
aGVHD组			10（45.4）		6（27.3）			6（27.3）
P			0.614^▲

组别		n		年龄/岁		性别				HLA相合程度
组别		n		年龄/岁		男	女			单倍体	全相合
健康对照组		25		32（29，49）		16（64.0）	9（36.0）			-
non-aGVHD组		18		46（22，53）		12（66.7）	6（33.3）			12（66.7）	6（33.3）
aGVHD组		22		42（28，51）		15（68.2）	7（31.8）			14（63.6）	8（36.4）
H、χ²或P				0.127		0.094				1.000^▲
组别	最终检测样本采血时间/d						预处理化疗强度
组别	最终检测样本采血时间/d						清髓性		减低剂量
健康对照组	-						-		-
non-aGVHD组	35.7±5.8						13（72.2）		5（27.8）
aGVHD组	44.1±18.3						17（77.3）		5（22.7）
t或P	1.862						0.731^▲
组别			原发病类型
组别			AML		ALL			MDS
健康对照组			-		-			-
non-aGVHD组			6（33.3）		4（22.2）			8（44.4）
aGVHD组			10（45.4）		6（27.3）			6（27.3）
P			0.614^▲

组别			n		cMo/%		iMo/%
健康对照组			25		79.80（76.05，83.85）		6.76（5.18，7.38）
non-aGVHD组			18		72.35（63.90，85.10）		8.91（5.37，17.18）
aGVHD组			22		62.20（54.78，79.00）^a		14.65（11.03，31.00）^ab
	JT				3.316^＊＊		5.104^＊＊
	H				11.400^＊＊		28.570^＊＊
组别				ncMo/%		IL-37/（ng/L）
健康对照组				5.29（4.05，6.95）		452.1（438.1，626.4）
non-aGVHD组				3.99（1.90，5.95）		385.9（364.5，440.6）^a
aGVHD组				4.19（3.07，7.97）		332.4（322.3，386.3）^a
		JT		1.232		5.914^＊＊
		H		2.986		32.240^＊＊

组别			n		cMo/%		iMo/%
健康对照组			25		79.80（76.05，83.85）		6.76（5.18，7.38）
non-aGVHD组			18		72.35（63.90，85.10）		8.91（5.37，17.18）
aGVHD组			22		62.20（54.78，79.00）^a		14.65（11.03，31.00）^ab
	JT				3.316^＊＊		5.104^＊＊
	H				11.400^＊＊		28.570^＊＊
组别				ncMo/%		IL-37/（ng/L）
健康对照组				5.29（4.05，6.95）		452.1（438.1，626.4）
non-aGVHD组				3.99（1.90，5.95）		385.9（364.5，440.6）^a
aGVHD组				4.19（3.07，7.97）		332.4（322.3，386.3）^a
		JT		1.232		5.914^＊＊
		H		2.986		32.240^＊＊

组别		n		年龄/岁		性别				HLA相合程度
组别		n		年龄/岁		男	女			单倍体	全相合
non-aGVHD组		18		46（22，53）		12（66.7）	6（33.3）			12（66.7）	6（33.3）
aGVHD组		12		42（28，51）		10（83.3）	2（16.7）			9（75.0）	3（25.0）
Z或P				0.106		0.419^▲				0.704^▲
组别	最终检测样本采血时间/d						预处理化疗强度
组别	最终检测样本采血时间/d						清髓性		减低剂量
non-aGVHD组	35.7±5.8						13（72.2）		5（27.8）
aGVHD组	37.1±6.8						6（50.0）		6（50.0）
t或P	0.594						0.266^▲
组别			原发病类型
组别			AML		ALL			MDS
non-aGVHD组			6（33.3）		4（22.2）			8（44.4）
aGVHD组			5（41.7）		3（25.0）			4（33.3）
P			0.894^▲